Allergan Aesthetics has launched its fourth annual CoolMonth promotion in April 2026, offering $400 off CoolSculpting® treatments for first-time users. This initiative aims to increase access to non-surgical fat reduction, capitalizing on growing consumer interest in body contouring, particularly following the rise in popularity of GLP-1 medications for weight management. The FDA-cleared procedure utilizes cryolipolysis to permanently eliminate fat cells with minimal downtime.
The increasing demand for non-invasive body contouring procedures reflects a broader societal shift towards aesthetic wellness and a desire for targeted fat reduction solutions. While weight loss medications like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are proving effective for overall weight management, they don’t always address localized pockets of stubborn fat. CoolSculpting® offers a complementary approach for individuals seeking to refine their body shape after achieving weight loss or for those with localized fat deposits resistant to diet and exercise. This promotion comes at a time when approximately 50% of individuals between 25 and 55 are considering body contouring treatments in preparation for warmer weather, according to a 2023 Allergan survey.
In Plain English: The Clinical Takeaway
- Fat Freezing: CoolSculpting® freezes and destroys fat cells, which are then naturally eliminated by the body over several weeks to months.
- Non-Surgical: Unlike liposuction, CoolSculpting® requires no incisions, anesthesia, or significant recovery time.
- Targeted Treatment: The procedure can be used to reduce fat in specific areas like the abdomen, flanks, thighs, and under the chin.
The Science Behind CoolSculpting®: Cryolipolysis and Apoptosis
CoolSculpting®, formally known as cryolipolysis, is based on the principle that fat cells are more vulnerable to cold temperatures than surrounding tissues. The procedure utilizes a specialized applicator to deliver controlled cooling to the targeted fat layer, inducing apoptosis – programmed cell death – in the fat cells. This process doesn’t damage the skin or surrounding tissues. The dead fat cells are then gradually removed from the body through the lymphatic system over a period of 1-3 months. The efficacy of cryolipolysis has been demonstrated in numerous clinical trials, with studies showing an average fat reduction of 20-25% in treated areas. [Cryolipolysis for Body Contouring: A Systematic Review]. The initial research, pioneered by Drs. R. Rox Anderson and Dieter Manstein at Massachusetts General Hospital, laid the groundwork for the development of the technology.
Geographical Access and Regulatory Oversight
CoolSculpting® is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of visible fat bulges in multiple areas of the body. In Europe, the procedure is regulated by the European Medicines Agency (EMA) and requires adherence to stringent safety standards. Access to CoolSculpting® varies depending on regional healthcare systems and the availability of qualified practitioners. In the United States, the procedure is typically offered in dermatology clinics, medical spas, and plastic surgery centers. The NHS in the United Kingdom does not currently offer CoolSculpting® as a standard treatment, as it is considered a cosmetic procedure. However, patients can access the treatment privately.
Funding and Bias Transparency
CoolSculpting® is manufactured and marketed by Allergan Aesthetics, an AbbVie company. Clinical trials supporting the efficacy and safety of CoolSculpting® have been funded by Allergan Aesthetics. While the company maintains rigorous scientific standards in its research, it’s important to acknowledge the potential for bias in studies funded by the manufacturer. Independent research and meta-analyses are crucial for providing a balanced assessment of the procedure’s benefits and risks.
“The key to successful cryolipolysis lies in precise applicator placement and parameter settings. Proper technique is essential to maximize fat reduction and minimize the risk of adverse events.” – Dr. Sabrina Fabi, Board-Certified Dermatologist and Clinical Investigator.
CoolSculpting® Elite: An Enhanced Technology
Allergan Aesthetics has introduced CoolSculpting® Elite, an updated version of the original CoolSculpting® system. CoolSculpting® Elite features an upgraded applicator design that allows for a larger treatment area and faster procedure times. This enhanced technology can potentially reduce treatment time by up to 50% and improve patient comfort. The CoolSculpting® Elite applicators are also designed to provide more consistent and uniform cooling, potentially leading to more predictable results.
| Feature | CoolSculpting® | CoolSculpting® Elite |
|---|---|---|
| Applicator Coverage | Smaller | Larger |
| Treatment Time | Longer | Shorter (up to 50% faster) |
| Cooling Consistency | Standard | Enhanced |
Contraindications & When to Consult a Doctor
CoolSculpting® is not suitable for everyone. Individuals with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria should not undergo the procedure. It is also not recommended for pregnant or breastfeeding women. Patients with pre-existing hernias or significant skin laxity may not be ideal candidates. Rare side effects, such as paradoxical adipose hyperplasia (PAH) – a visible enlargement in the treated area – can occur in approximately 0.025% to 0.39% of cases. FDA Safety Communication. Consult a board-certified dermatologist or plastic surgeon if you experience any unusual swelling, pain, or changes in the treated area after the procedure. Individuals with a history of skin sensitivity or allergies should inform their provider before treatment.
The Future of Non-Invasive Fat Reduction
The field of non-invasive fat reduction is rapidly evolving, with ongoing research into new technologies and techniques. Emerging modalities include radiofrequency-based treatments, ultrasound-based treatments, and injectable lipolysis. The combination of different technologies may offer synergistic benefits and further improve treatment outcomes. Long-term studies are needed to assess the durability of results and the potential for long-term side effects associated with these procedures. The continued development of personalized treatment plans, tailored to individual patient needs and body characteristics, will be crucial for optimizing results and ensuring patient satisfaction.
References
- Stevens WG, Eagan MM, Felber C, Sarhaddi D, Orlando MV. Cryolipolysis. The Art of Combining Surgical and Nonsurgical Techniques in Aesthetic Medicine. Thieme; 2018:132-149.
- Avram MM, Harry RS. Cryolipolysis™ for subcutaneous fat layer reduction. Lasers in Surgery and Medicine 2009 Dec;41(10):703-8.
- FDA. CoolSculpting Fat Freezing Procedure: Rare Side Effect Causing Visible Lumps Under Skin. https://www.fda.gov/medical-devices/safety-communications/coolsculpting-fat-freezing-procedure-rare-side-effect-causing-visible-lumps-under-skin
- Shapiro, R., & Zelickson, B. (2016). Cryolipolysis: destroying fat cells. Seminars in Cutaneous Medicine and Surgery, 35(1), 4–8. https://pubmed.ncbi.nlm.nih.gov/27013361/
